Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial

  1. Rohde, G.
  2. Stenglein, S.
  3. Prozesky, H.
  4. Manudhane, G.
  5. Sandulescu, O.
  6. Bauer, M.
  7. Overend, T.
  8. Koch, W.
  9. Neuschwander, D.
  10. Planz, O.
  11. Torres, A.
  12. Witzenrath, M.
Journal:
eClinicalMedicine

ISSN: 2589-5370

Year of publication: 2023

Volume: 65

Type: Article

DOI: 10.1016/J.ECLINM.2023.102237 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus